GRAY SUSANNAH — SEC Form 4 filings
SEC reporting owner CIK 1833453. 12 Form 4 filings on record with FilingPulse; latest filed 2026-06-18.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-05-10 to 2026-06-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | Director | 3 | — | — | 6 |
| Morphic Holding, Inc. (MORF) | Director | 2 | — | — | 5 |
| 4D Molecular Therapeutics, Inc. (FDMT) | Director | 3 | — | — | 3 |
| MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) | Director | 3 | — | — | 3 |
| ANAPTYSBIO, INC (ANAB) | Director | 1 | — | — | 1 |
Form 4 filings — GRAY SUSANNAH
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-18 | 4 | 4D Molecular Therapeutics, Inc. (FDMT) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Theravance Biopharma, Inc. (TBPH) | Grant/award (A): 6,009 @ $0 · Grant/award (A): 13,398 (derivative) @ $0 | EDGAR |
| 2026-05-28 | 4 | MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) | Grant/award (A): 46,293 @ $0 | EDGAR |
| 2026-04-29 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 11,250 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | 4D Molecular Therapeutics, Inc. (FDMT) | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) | Grant/award (A): 89,139 @ $2.16 | EDGAR |
| 2025-05-21 | 4 | Theravance Biopharma, Inc. (TBPH) | Grant/award (A): 10,649 @ $0 · Grant/award (A): 24,258 (derivative) @ $0 | EDGAR |
| 2024-08-20 | 4 | Morphic Holding, Inc. (MORF) | Disposition to issuer (D): 18,111 (derivative) · Disposition to issuer (D): 17,550 (derivative) · Disposition to issuer (D): 12,535 (derivative) · Disposition to issuer (D): 23,168 (derivative) | EDGAR |
| 2024-06-05 | 4 | Morphic Holding, Inc. (MORF) | Grant/award (A): 23,168 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) | Grant/award (A): 20,645 @ $10.78 | EDGAR |
| 2024-05-23 | 4 | 4D Molecular Therapeutics, Inc. (FDMT) | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2024-05-10 | 4 | Theravance Biopharma, Inc. (TBPH) | Grant/award (A): 10,537 @ $0 · Grant/award (A): 23,576 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1833453 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →